NASDAQ:SLRX Salarius Pharmaceuticals Q1 2024 Earnings Report $0.79 +0.00 (+0.34%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings History Salarius Pharmaceuticals EPS ResultsActual EPS-$3.28Consensus EPS -$53.60Beat/MissBeat by +$50.32One Year Ago EPSN/ASalarius Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASalarius Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/13/2024TimeN/AConference Call DateMonday, May 13, 2024Conference Call Time4:00PM ETUpcoming EarningsSalarius Pharmaceuticals' Q1 2025 earnings is scheduled for Thursday, August 7, 2025Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Salarius Pharmaceuticals Earnings HeadlinesSalarius Pharmaceuticals faces Nasdaq delisting over rule breachesApril 27, 2025 | investing.comSalarius Pharmaceuticals announces Langer to join SABApril 17, 2025 | markets.businessinsider.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 21, 2025 | Golden Portfolio (Ad)Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory BoardApril 16, 2025 | globenewswire.comSalarius Pharmaceuticals sees cash runway through later part of 2Q25March 26, 2025 | markets.businessinsider.comSalarius Pharmaceuticals reports FY24 EPS ($5.79) vs. ($30.74) last yearMarch 26, 2025 | markets.businessinsider.comSee More Salarius Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Salarius Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Salarius Pharmaceuticals and other key companies, straight to your email. Email Address About Salarius PharmaceuticalsSalarius Pharmaceuticals (NASDAQ:SLRX), a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.View Salarius Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings Copart (5/22/2025)Ross Stores (5/22/2025)Analog Devices (5/22/2025)Workday (5/22/2025)Autodesk (5/22/2025)Intuit (5/22/2025)Toronto-Dominion Bank (5/22/2025)Bank of Nova Scotia (5/27/2025)AutoZone (5/27/2025)PDD (5/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
